Answers are grounded in this paper and cite their sources.
Infection with SARS-COV-2 is the cause of COVID-19 and has generated an unprecedented health crisis worldwide. While most of the patients experience mild symptoms, around 20% develop severe disease, characterized by pneumonia and in the worst cases by acute respiratory distress syndrome (ARDS). 1 The analysis and understanding of the immune responses arising in the course of SARS-COV-2 infection may help to propose therapeutic solutions. Due to the crucial role of Natural Killer (NK) cells in antiviral immune responses, 2 we analyzed NK cells in blood from a cohort of 82 individuals: 10 healthy controls (HC), 10 paucisymptomatic COVID-19 patients (pauci), 34 patients with pneumonia (pneumo) and 28 patients with ARDS due to SARS-CoV-2 infection. The absolute numbers of peripheral blood NK cells, B, CD4 + , and CD8 + T lymphocytes were lower in the pneumonia and ARDS groups than in healthy controls, consistent with previously published results 3 (Fig. 1a ). We investigated the NK cell subsets further and found that among CD45 + CD3 − CD56 + total NK cells the proportion of mature NK cells, a subset defined on the basis of its expression of the CD16 and CD57 cell surface receptors, was markedly lower in patients with ARDS (Fig. 1b ). Given their role in viral infection, the loss of mature NK cells may contribute to the pulmonary complications occurring in the most severe cases of COVID-19. We then focused our analysis on molecular pathways likely to improve NK cell antiviral activity to promote SARS-CoV-2 clearance, and analyzed the expression of several immune checkpoints. Given the availability of therapeutic monoclonal antibodies blocking the immunosuppressive functions of PD-1, 4 NKG2A, 5 and CD39 6 initially developed for cancer therapies, we analyzed the expression of these molecules on NK cells in our cohort. PD-1 and NKG2A are cell surface receptors, and their engagement with their ligands, PD-L1 and HLA-E, respectively, inhibits the function of T and NK cells. CD39 is an ectoenzyme that cleaves extracellular ATP and ADP, which can be released from dead cells upon viral infection, leading to the generation of adenosine, which has strong immunosuppressive effects on T and NK cells. Fig. 1 COVID-19 is associated with lymphopenia and a dysfunctional NK cell phenotype. a Absolute numbers of circulating NK, B, CD4 + and CD8 + T cells per microliter of peripheral blood from healthy donors and COVID-19 patients. b Left: UMAP projection of concatenated peripheral CD45 + CD3 − CD56 + NK cells from all samples identifies 3 NK clusters: CD16 - CD57 − , CD16 + CD57 − and CD16 + CD57 + . Right: UMAP projections of concatenated peripheral blood NK cells from healthy donors and COVID-19 patients. Red indicates the highest cell density. c Phenotyping of NK cells in peripheral blood from healthy donors and COVID-19 patients. The percentages of total NK cells and MedFI for marker-positive NK cells are shown. d Percentages of CD16 + CD57 + , CD16 + CD57 − , and CD16 − CD57 − subsets in CD45 + CD3 − CD56 + NK cells in the blood of HCs (white) and ARDS patients (red) and BALF from ARDS patients (red). e Representative flow cytometry contour plots from three ARDS patients showing CD39, PD-1, and NKG2A expression (red) vs. fluorescence minus one (FMO, black) on NK cells from BALF. f Percentages of CD39 + , PD-1 + and NKG2A + NK cells, cells in blood (black) and BALF (red) from the same ARDS patients. g Specific K562-HLA-E lysis by NK cells isolated from ARDS PBMCs incubated with medium (black), isotype control (IC, blue) or monalizumab (red). a-g , Each symbol represents a single donor. Experimental conditions and statistics details are provided in supplementary material. Full size image
No takes yet. Share an insight, caveat, or question.
Demaria et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: